Regado Biosciences Establishes Medical Advisory Board

BASKING RIDGE, N.J., June 2 /PRNewswire/ -- Regado Biosciences, Inc., a
privately held company leading the development of antithrombotic therapeutic
aptamers with active control agents, today announced the establishment of its
Medical Advisory Board (MAB). Regado's MAB is comprised of leaders in the
fields of cardiology, thrombosis and coagulation, and cardiovascular surgery.
These highly regarded leaders will advise the Company on its clinical programs
and provide strategic guidance to support the eventual commercialization of
Regado's products, in particular, the Company's leading product candidate, the
REG1 anticoagulation system.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado,
stated, "We are delighted to announce the formation of our MAB and look
forward to the knowledge, guidance and creativity that they will bring to our
development programs. We expect that our Medical Advisory Board will be
instrumental in the achievement of Regado's strategic imperatives and
considered ourselves privileged to welcome this extremely accomplished group
of physicians to our company."

Robert Harrington, MD, Director of the Duke Clinical Research Institute and
Chairman of Regado's Medical Advisory Board, added, "This advisory board
comprises talented, respected and objective physician-investigators. Their
expertise, judgment and clinical experience will be important to the continued
development of the REG1 anticoagulation system and to Regado technology in
general. I am honored to chair this renowned group."

Regado's Medical Advisory Board is comprised of the following members:
-- Robert A. Harrington, MD, (Chairman of the Medical Advisory Board),
Professor of Medicine and Director, Duke Clinical Research Institute,
Duke University, Durham, North Carolina
-- Paul W. Armstrong, MD, Professor of Medicine, Division of Cardiology,
University of Alberta, Edmonton, Alberta, Canada and Director of the
Canadian VIGOUR Centre (Virtual Coordinating Centre for Global
Collaborative Cardiovascular Research)
-- Richard C. Becker, MD, Professor of Medicine and Director of the
Cardiovascular Thrombosis Center, Duke Clinical Research Institute,
Duke University, Durham, North Carolina
-- Robert M. Califf, MD, (Special Advisor to Regado Biosciences, Inc. and
ex officio member of the Medical Advisory Board), Vice Chancellor for
Clinical Research and Professor of Medicine, Division of Cardiology,
Duke University Medical Center and Director, Duke Translational
Medicine
Institute, Duke University, Durham, North Carolina
-- Michael Gibson, MD, Associate Professor of Medicine and Chief,
Clinical
Research, Cardiovascular Division, Beth Israel Deaconess Medical
Center,
Harvard Medical School, Harvard University, Boston, Massachusetts
-- Neal S. Kleiman, MD, Medical Director, Cardiac Catheterization
Laboratories, The Methodist DeBakey Heart Center, The Methodist
Hospital, Houston, Texas and Professor of Medicine, Weill Medical
College, Cornell University
-- A. Michael Lincoff, MD, Director, Cleveland Clinic Coordinating Center
for Clinical Research (C5Research); Director, Center for Clinical
Research and Vice Chairman, Lerner Research Institute and Vice
Chairman,
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
Ohio
-- Roxana Mehran, MD, Joint Chief Scientific Officer, Clinical Trial
Center, Cardiovascular Research Foundation, New York, New York and
Associate Professor of Medicine, Columbia University Medical Center,
Columbia University, New York, New York

-- Harvey White, DSc, Honorary Clinical Professor of Medicine, University
of Auckland and Director of Coronary Care and Green Lane
Cardiovascular
Research Unit, Auckland City Hospital, Auckland, New Zealand

About Regado Biosciences, Inc.

Regado Biosciences is pioneering a new therapeutic technology with the
creation and development of two-component drug systems. Each system is
comprised of a nuclease-stabilized RNA aptamer therapeutic that can be
controlled directly by its specific and complementary oligonucleotide active
control agent. This technology is being applied initially to acute care
injectable antithrombotics, a multi-billion dollar market in need of
therapeutics with improved safety profiles and a greater degree of therapeutic
control. Regado's technology is designed to give physicians the ability to
actively and directly control each system's therapeutic effect providing a
safe and unique approach to personalized medicine.

Regado's lead program, REG1, is comprised of two parenteral agents, the first
being a potent and highly selective Factor IXa inhibitor (RB006) and the
second being its complementary active control agent (RB007). RB007 can be
used to completely or partially reverse the anticoagulant effect of RB006.
Regado recently completed a phase 2a study of REG1 in percutaneous coronary
intervention (PCI) and is planning the initiation of a rigorous phase 2b
program in this same indication in 3Q2009.

More information can be found at http://www.regadobio.com

SOURCE Regado Biosciences, Inc.

Ellen McDonald, Chief Business Officer for Regado Biosciences, Inc.,
+1-908-580-2113, emcdonald@regadobio.com